J.P. Morgan analyst Cory Kasimov maintained a Buy rating on BioMarin Pharmaceutical (NASDAQ:BMRN) on Wednesday, setting a price target of $131, which is approximately 73.19% above the present share price of $75.64.
Kasimov expects BioMarin Pharmaceutical to post earnings per share (EPS) of -$0.16 for the third quarter of 2020.
The current consensus among 24 TipRanks analysts is for a Moderate Buy rating of shares in BioMarin Pharmaceutical, with an average price target of $111.13.
The analysts price targets range from a high of $188 to a low of $77.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $429.49 million and a net profit of -$40.93 million. The company's market cap is $13.72 billion.
According to TipRanks.com, J.P. Morgan analyst Cory Kasimov is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.7% and a 54.32% success rate.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.